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A variety of environmental, carcinogenic, and chemothera-
peutic agents form bulky lesions on DNA that activate DNA
damage checkpoint signaling pathways in human cells. To iden-
tify the mechanisms by which bulky DNA adducts induce dam-
age signaling, we developed an in vitro assay using mammalian
cell nuclear extract and plasmid DNA containing bulky adducts
formed byN-acetoxy-2-acetylaminofluorene or benzo(a)pyrene
diol epoxide. Using this cell-free system together with a variety
of pharmacological, genetic, and biochemical approaches, we
identified the DNA damage response kinases DNA-dependent
protein kinase (DNA-PK) and ataxia telangiectasia mutated
(ATM)asbulkyDNAdamage-stimulatedkinases thatphosphor-
ylate physiologically important residues on the checkpoint pro-
teins p53, Chk1, and RPA. Consistent with these results, puri-
fied DNA-PK and ATM were directly stimulated by bulky
adduct-containing DNA and preferentially associated with
damaged DNA in vitro. Because the DNA damage response
kinase ATMandRad3-related (ATR) is also stimulated by bulky
DNA adducts, we conclude that a common biochemical mecha-
nism exists for activation of DNA-PK, ATM, and ATR by bulky
adduct-containing DNA.
Environmental carcinogens, such as UV light and benzo-
(a)pyrene, form bulky base adducts on DNA that interfere with
many aspects of DNAmetabolism, including transcription and
DNA replication. To minimize the detrimental effects of DNA
damage on genome stability and cell viability, signal transduc-
tion pathways termed DNA damage checkpoints delay or pre-
vent cell cycle progression to allow time for DNA repair (1, 2).
This DNA damage response (DDR)2 is composed of a cascade
of protein phosphorylation events that ultimately determines
cell fate. Defects in the repair or response to bulky DNA
adducts are associated with a number of human disorders,
including neurodegeneration and cancer (1, 2).
Initiation of the DDR is governed by protein kinases and
accessory factors that directly sense the DNA damage and then
respond by phosphorylating and activating additional protein
factors that control cell cycle progression, DNA repair, and
apoptosis (1, 2). In humans, DDR signaling is initiated by
the phosphoinositide 3-kinase-related protein kinases (PIKKs)
ATR, ATM, and DNA-PK (1, 2).
Although many proteins become phosphorylated in cells
exposed to genotoxic stressors (3), the DDR transducer and
effector proteins p53, Chk1 (checkpoint kinase 1), and replica-
tion protein A (RPA) play well recognized roles in controlling
DNA repair, cell cycle progression, and cell fate (2, 4–7). Upon
DNA damage, all three proteins become phosphorylated on
specific amino acid residues that regulate their DNA damage
checkpoint functions. The phosphorylation status of these pro-
teins can therefore be used as a common biochemical read-out
for activation of the DDR.
Precisely how bulky DNA adducts are sensed by the cell to
elicit DNA damage checkpoint responses is not completely
understood. Evidence from many model systems, including
yeast, Xenopus egg extracts, and mammalian cells, indicates
that the stalling of RNA and DNA polymerases at bulky DNA
base adducts during transcription and DNA replication serves
as a potent inducer of theDNAdamage checkpoint response (1,
2, 8, 9). Similarly, the repriming of DNA synthesis downstream
of bulky DNA adducts, which leaves postreplication gaps
throughout the genome, may also serve as a signal for check-
point activation (10, 11). Furthermore, the actual removal of
bulkyDNA adducts by the process of nucleotide excision repair
leaves short 24–32-single-stranded DNA (ssDNA) gaps that
may also activate this response (12–17). Based on these data,
current models propose that the generation of ssDNA, a com-
mon intermediate at sites of repair and transcription and repli-
cation stalling, serves as the trigger for DNA damage check-
point activation. According to this model, this ssDNA rapidly
becomes bound by the major eukaryotic ssDNA-binding pro-
tein RPA. Through a direct interaction of the ATR-interacting
protein ATRIP (ATR-interacting protein) with the 70-kDa
RPA1 subunit of RPA, ATR can be recruited to sites of DNA
damage to initiate signaling responses to bulky DNA damage
(18–20).
However, several other lines of evidence suggest that alter-
nativemechanisms exist for initiatingDNAdamage checkpoint
* This work was supported by National Institutes of Health grant GM32833 (to
A. S.).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. 1 and 2.
1 To whom correspondence should be addressed: Dept. of Biochemistry and
Biophysics, Campus Box 7260, University of North Carolina School of Med-
icine, Chapel Hill, NC 27599. Tel.: 919-962-0115; Fax: 919-966-2852; E-mail:
aziz_sancar@med.unc.edu.
2 The abbreviations used are: DDR, DNA damage response; AAF, N-acetoxy-
2-acetylaminofuorene; BPDE, benzo(a)pyrene diol epoxide; RPA, replica-
tion protein A; PIKK, phosphoinositide 3-kinase-related kinase; ATM, ataxia
telangiectasia mutated; ATR, ATM and Rad3-related; DNA-PK, DNA-depen-
dent protein kinase; DNA-PKcs, DNA-dependent protein kinase catalytic
subunit.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 22, pp. 19237–19246, June 3, 2011
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
JUNE 3, 2011 • VOLUME 286 • NUMBER 22 JOURNAL OF BIOLOGICAL CHEMISTRY 19237
responses to bulky lesions, including through the direct recog-
nition of bulky DNA adducts by either ATR alone or in combi-
nation with its kinase-activating protein partner TopBP1
(topoisomerase II-binding protein) (21–24). Similarly, direct
protein-protein interactions of ATR with various nucleotide
excision andmismatch repair factorsmay also control the DDR
to different forms of DNA base damage (25–29). It therefore
remains unclear whether additional pathways may control the
cellular response to bulky DNA adducts.
To gain new insights into the mechanisms of DNA damage
checkpoint activation by bulkyDNA lesions, we designed a cell-
free assay using mammalian cell nuclear extract, damaged
DNA, and checkpoint target protein substrates. Importantly,
this in vitro system induces robust checkpoint responses,
including the phosphorylation of Chk1, p53, and RPA on resi-
dues essential for checkpoint responses in vivo. Furthermore,
these responses occur independent of DNA repair, transcrip-
tion, replication, and chromatin modification. Using this assay,
we have discovered that bulky DNA adducts directly activate
the protein kinases DNA-PK and ATM to phosphorylate mul-
tiple checkpoint target proteins.
EXPERIMENTAL PROCEDURES
Cell Lines—TheChinese hamster ovary (CHO) cell linesAA8
and V3 (gift fromDale Ramsden, University of North Carolina)
were grown in-minimumEagle’smedium supplementedwith
10% (v/v) fetal bovine serum (FBS) and penicillin/streptomycin.
M059K (ATCC CRL-2365) and M059J (ATC CRL-2366) cells
were maintained in DMEM/F-12 containing 10% FBS and pen-
icillin/streptomycin. The SV40-immortalized XP-A fibroblast
cell line XP20S (30) was grown in DMEM plus 10% FBS and
penicillin/streptomycin. Nuclear extracts were prepared from
either adherent cells (150-mm plates) or suspension cells,
essentially as described previously (31). Extracts were dialyzed
overnight against Buffer D (25 mM HEPES-KOH, pH 7.9, 100
mMKCl, 10% (v/v) glycerol, 0.2mMEDTA, 1mMDTT).Nuclear
extract concentrations ranged from 3 to 8 mg/ml using the
Bio-Rad protein assay with bovine serum albumin (BSA) as a
standard.
Protein Purification—Kinase-dead, hexahistidine-tagged
Chk1 was expressed in Sf21 cells and purified using nickel-
NTA-agarose, as described previously (21). RPA was expressed
in BL21 (DE3) cells and purified as described previously (32,
33). GST-tagged, full-length p53 (Addgene plasmid 10852) (34)
was expressed in BL21 (DE3) cells and purified with glutathi-
one-Sepharose 4B (Amersham Biosciences) resin according to
the manufacturer’s recommendations. Purified DNA-PK was
purchased from Promega (catalog no. V581A). FLAG-tagged
ATM kinase was expressed in HEK293 cells and purified using
anti-FLAG-agarose (Sigma), as described previously (35).
Chemicals and Antibodies—TheDNA-PK inhibitor NU7026
and ATM inhibitor KU-55933 were purchased from Sigma and
dissolved in DMSO. N-acetoxy-2-acetylaminofluorene (AAF)
and benzo(a)pyrene diol epoxide (BPDE) were obtained from
the NCI Chemical Carcinogen Repository (Midwest Research
Institute, Kansas City, MO). Caffeine and cisplatin were pur-
chased from Sigma.
The following primary antibodies were obtained from the
indicated companies and used at the indicated dilution: from
Cell Signaling Technology, phospho-Chk1-Ser317 (catalog no.
2344, 1:10,000), phospho-Chk1-Ser345 (catalog no. 2348,
1:10,000), phospho-p53-Ser15 (catalog no. 9284, 1:10,000), and
PARP (catalog no. 9542, 1:1000); from Bethyl Laboratories,
RPA70 (catalog no. A300-241A, 1:2000) and phospho-RPA2-
Ser33 (catalog no. A300-246A, 1:10,000); from Santa Cruz Bio-
technology, Inc., ATM (catalog no. 2C1, 1:1000), ATR (catalog
no.N-19, 1:1000), XPB (catalog no. S-19, 1:2000), Chk1 (catalog
no. G-4, 1:2000), GST (catalog no. B-14, 1:1000), andKu80 (cat-
alog no. H-300, 1:2000); fromNeomarkers, DNA-PKcs (catalog
no. MS-423, 1:2000) (this antibody was also used for immu-
nodepletion); from Calbiochem, RPA2 (catalog no. NA18,
1:2000) and the anti-ATM antibody (catalog no. PC116) used
for immunodepletion.
Depletion of DNA-PKcs, ATM, and ATR from Nuclear
Extract—DNA-PKcs and ATM were immunodepleted from
XP-A nuclear extract (30 g) by using two sequential 3-h incu-
bations (4 °C) with 10 g of antibody bound to 30 l of recom-
binant Protein A/G Plus-agarose (catalog no. E1010; Santa
Cruz Biotechnology, Inc.). Mock depletions were carried out in
a similar manner with either mouse or rabbit IgG (Santa Cruz
Biotechnology, Inc.). ATR was depleted by incubating XP-A
nuclear extract (30 g) twice (3 h, 4 °C) with 150 g of GST-
tagged TopBP1 fragment (amino acids 978–1192) bound to
glutathione-Sepharose 4B (Amersham Biosciences). Incuba-
tion of extract with free glutathione resin was used as a mock
depletion.
Preparation of DNA Substrates—AAF- and BPDE-damaged
pUC19 DNA (pUC19) were prepared as described previously
(21, 22). Cisplatin-damaged DNA was prepared by treating
pUC19 plasmid DNA with 10 or 100 M cisplatin for 18 h at
37 °C in 10 mM Tris, pH 8.0. Linearized plasmid DNAs were
prepared by digestion with the restriction endonuclease EcoRI
(New England Biolabs). The nicking plasmid pBC-KS.nick
was created by ligating oligonucleotides containing the target
sequence for the nicking endonuclease Nt.Bbv.CI into the XbaI
and HindIII sites of pBC-KS (Stratagene). The sequences of
these oligonucleotides are available upon request. Biotinylated
damaged and undamaged DNA immobilized on Dynabeads
M-280 Streptavidin (Invitrogen) was prepared as described
previously (36).
Kinase Assays—Kinase reactions, unless otherwise stated,
contained nuclear extract (300 ng of XP-A, M059K, or M059J
nuclear extract; 5 g of CHO AA8 or V3 nuclear extract), a
checkpoint substrate (10 nM Chk1, 10 nM p53, or 30 nM RPA),
and 200 ng of DNA (11.5 nM) or buffer (10 mM Tris, pH 8.5) in
10 l of 32 mM HEPES-KOH, pH 7.9, 50 mM KCl, 3.2 mM
MgCl2, 2% (v/v) glycerol, 1 mM DTT, 1 mM ATP, 10 g/ml
creatine phosphokinase, and 5 mM phosphocreatine. Reactions
were incubated at 37 °C for 12 min and then stopped by the
addition of 10l of 2 SDS-PAGE sample buffer (100mMTris,
pH 6.8, 10% (v/v) glycerol, 200 mM DTT, 2% (w/v) SDS, 0.01%
(w/v) bromphenol blue). Samples were boiled and electro-
phoresed on SDS gels. After transfer to nitrocellulose, blots
were probed overnight with the appropriate phospho-specific
antibody. After secondary antibody incubation, chemilumines-
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cent signals were visualized with Amersham Biosciences ECL
Plus or ECL Advance Western blotting detection reagents (GE
Healthcare). Blots were reprobed to detect total checkpoint
substrate protein levels. Blots were scanned, and signals were
quantified using ImageQuant version 5.0 software (GE Health-
care). The highest phosphorylation signal on each blot was set
to 100%, and the levels of phosphorylation of other samples
were expressed relative to this value. Graphed values are the
average and S.D. values from 2–4 independent experiments.
Kinase assayswith purifiedDNA-PKandATMwere performed
using identical reaction conditions butwith the purified protein
kinases at a final concentration of 0.15 nM.
DNA Binding Assays—The association of proteins with
immobilized damaged and undamaged DNAwas performed as
described previously (36), except that proteins were incubated
in 20 l of kinase reaction buffer lacking ATP. After incubation
of the indicated proteinswith immobilizedDNA (250 ng) for 20
min at room temperature, the DNA-beads were washed three
times with wash buffer (25 mM HEPES-KOH, pH 7.9, 50 mM
KCl, 10% (v/v) glycerol, 0.02% (v/v) Nonidet P-40) and then
boiled in 1 SDS-PAGE sample buffer.
RESULTS
Bulky DNA Adducts Induce Phosphorylation of Multiple
Checkpoint Substrate Proteins in a Cell-free System—To deter-
mine whether bulky DNA adducts can directly induce DNA
damage checkpoint signals in the absence of nucleotide exci-
sion repair or stalling of DNA and RNA polymerases, we
designed a simple, cell-free assay composed of mammalian
cell nuclear extract, damaged plasmid DNA, and various
checkpoint substrate proteins. Although reactions were sup-
plemented with ATP and an ATP regeneration system, the
reactions lacked ribonucleotides and deoxyribonucleotides
required for RNA transcription and DNA replication, re-
spectively. We initially used nuclear extract from a nucleo-
tide excision repair-deficient XP-A cell line as a source of
DNA damage checkpoint signaling factors to ensure that the
response was independent of nucleotide excision repair. A
highly sensitive, in vitro excision repair assay (37) confirmed
that no detectable repair occurred under these reaction con-
ditions (data not shown). The initial source of damaged DNA
was circular plasmid DNA (pUC19) treated with the carcin-
ogen AAF, which primarily forms adducts on the C8 position
of guanines. The dose of AAF used was sufficient to yield
20–30 adducts/plasmid (38).
The read-out for the assay involvedmonitoring the phosphor-
ylation status of various checkpoint substrate proteins with
phospho-specific antibodies and immunoblotting. We initially
used the tumor suppressor protein p53 as a substrate because its
phosphorylation on Ser15 in cells treated with DNA-damaging
agents stabilizes the protein and allows it to regulate transcription
of specific target genes involved in DNA repair, cell cycle arrest,
and apoptosis (2). As shown in Fig. 1A, p53 phosphorylation was
stimulated 3-fold in reactions containing AAF-damaged (mod-
ified) DNA in comparisonwith reactions containing only undam-
aged (unmodified) plasmid DNA.
We next tested Chk1 as a substrate because it is involved in
several aspects of the cellular response to DNA damage (4, 39),
including cell cycle checkpoints, transcription, DNA repair,
and apoptosis. Phosphorylation of Chk1 on two residues
(Ser317 and Ser345) by upstream DNA damage response
kinases is essential for its DNA damage checkpoint activities
in vivo (40). As shown in Fig. 1B, Chk1 phosphorylation on
Ser345 was stimulated 5-fold in reactions containing AAF-
damaged DNA in comparison with reactions containing only
undamaged DNA.
RPA, which functions in many DNA metabolic processes,
becomes phosphorylated in genotoxin-treated cells onmultiple
residues within theN-terminal region of the 34-kDa RPA2 sub-
unit of RPA (6, 7). We chose to examine Ser33 phosphorylation
because phosphorylation of this residue is important for inhib-
iting DNA replication in UV-treated human cells (5). As shown
in Fig. 1C, phosphorylation of this residuewas stimulated 3-fold
in reactions with bulky DNA adducts relative to reactions con-
taining only undamaged plasmid DNA. We also note the pres-
ence of a characteristic, slower migrating form of RPA2
observed in reactions containing AAF-treated DNA. Based on
the examination of Chk1, p53, and RPA phosphorylation on
physiologically important residues, we conclude that multiple
FIGURE 1. The checkpoint target proteins p53, Chk1, and RPA are phosphorylated in vitro in response to bulky adduct-containing DNA. Kinase
reactions were performed as described under “Experimental Procedures” and contained 300 ng of XP-A nuclear extract and 200 ng of umodified (UM) or
AAF-modified (M) pUC19 plasmid DNA. Reactions were supplemented with one of the following substrates: GST-p53 (A), His-Chk1 (B), or RPA (C) and were
stopped after 10 min. The phosphorylation status of each substrate was monitored using SDS-PAGE and immunoblotting with the indicated phospho-specific
antibody (p53, Ser15; Chk1, Ser345; RPA, RPA2 Ser33). All reactions were performed three times, and the phosphorylation signals for the reactions with AAF-
modified DNA were assigned the arbitrary value of 100%. The graphs show the average and S.D. values (error bars) from three independent experiments. For
each substrate, significantly more phosphorylation was induced in reactions containing AAF-modified DNA (paired t tests, p  0.05). The band shown in the
RPA2-P immunoblot represents the slower mobility form of RPA2 that is observed when probing for total RPA2.
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checkpoint target proteins become phosphorylated in a bulky
DNA adduct-stimulated manner in this cell-free system.
Characterization of the in Vitro Bulky DNA Damage Check-
point Assay—We next optimized the in vitro checkpoint reac-
tion to determine the factors and conditions important for the
robust phosphorylation of checkpoint substrates. We chose to
focus on Chk1 as a substrate in most of these experiments;
however, key experiments were repeated with p53 and RPA as
substrates, and similar results were observed. As shown in Fig.
2A, reactions containing AAF-damaged DNA and varying
amounts of nuclear extract generated more Chk1 phosphory-
lation than reactions lacking DNA or containing only undam-
aged plasmid DNA (compare lanes 9–12 with lanes 1–8).
Control reactions lacking either ATP, nuclear extract, or
recombinant Chk1 failed to yield any detectable Chk1 phos-
phorylation (data not shown). Importantly, the degree of Chk1
phosphorylation correlated well with the amount of damaged
DNA in the reaction, reaching 5-fold above that observed in
reactions lacking DNA or containing only undamaged DNA
(Fig. 2B). Moreover, as shown in Fig. 2C, phosphorylation of
Chk1 occurred rapidly, peaking 10–15min after the addition of
damaged DNA to the reaction.We conclude from these results
that checkpoint activation can be directly and rapidly induced
by bulky adduct-containing DNA in a cell-free system by a
mechanism independent of DNA repair, transcription stalling,
or DNA replication stress.
Bulky DNA Adducts Induce Checkpoint Activation Indepen-
dent of DNAEnds orNicks—Todeterminewhether other forms
of DNA damage are capable of directly inducing checkpoint
activation in this cell-free system, we treated circular pUC19
plasmid DNA with BPDE, an environmental carcinogen and
metabolic derivative of the polyaromatic hydrocarbon benzo-
(a)pyrene. LikeAAF, BPDE forms bulky base lesions on guanine
residues. The treatment conditions we used resulted in 20
adducts/plasmid (41). The addition of BPDE-modified DNA to
reactions containing nuclear extract andChk1 induced5-fold
more phosphorylation of Chk1 than reactions lacking DNA or
containing only undamaged DNA (Fig. 3A). Importantly, phos-
phorylation was observed on both Ser317 and Ser345, two resi-
dues critical for Chk1 function in DNA damage checkpoints.
We also examined plasmid DNA treated with the chemothera-
FIGURE 2. Development of a cell-free assay for studying bulky DNA dam-
age signaling. A, kinase reactions containing either no DNA or 200 ng (11.5
nM) of unmodified (UM) or AAF-modified (M) circular pUC19 plasmid DNA
were prepared with increasing amounts of nuclear extract (100 ng, 300 ng, 1
g, and 3 g) from XP-A cells. Reactions were stopped after 12 min, fraction-
ated on SDS-PAGE, transferred to nitrocellulose, and then probed with the
indicated antibodies. Significantly more Chk1 phosphorylation was observed
in reactions containing modified DNA than in reactions lacking DNA or con-
taining only undamaged DNA (reactions containing 0.3, 1, or 3 g of nuclear
extract; paired t tests, p  0.05). B, unmodified or AAF-modified plasmid DNA
was titrated into kinase reactions. Reactions contained 0, 0.35, 0.7, 1.4, 2.9, 5.7,
or 11.5 nM DNA and were stopped after 12 min. Chk1 phosphorylation in
reactions containing AAF-modified DNA was significantly different from in
reactions containing unmodified DNA at DNA concentrations of 2.9, 5.7, and
11.5 nM (paired t tests, p  0.05). C, kinase reactions containing 300 ng of XP-A
nuclear extract and either no DNA or 200 ng of unmodified DNA were incu-
bated for the indicated lengths of time. Significantly more Chk1 phosphory-
lation was observed at 3, 9, and 15 min in reactions containing modified DNA
than in reactions lacking DNA or containing only unmodified DNA (paired t
tests, p  0.05). All graphs show the average and S.D. values (error bars) from
2–3 independent experiments.
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peutic agent cisplatin. However, even at the highest concentra-
tion of cisplatin, we observed only a small, 2-fold increase in
Chk1 phosphorylation relative to reactions containing undam-
aged DNA (Fig. 3B). Although cisplatin induces a variety of
intra- and interstrand cross-links in DNA, the major cisplatin
adduct 1,2-d(GpG) occurs between adjacent guanine residues
and does not significantly distort the DNA duplex. The 1,2-
d(GpG) adduct is a relatively poor substrate for nucleotide exci-
sion repair in comparison with AAF-guanine and 1,3-d(GTG)
cisplatin adducts (42, 43). These results therefore indicate that
only bulkier, helix-distorting adducts, such as AAF and BPDE,
are capable of efficiently inducing checkpoint activation in this
in vitro system.
Because double strand breaks inDNA are a potent inducer of
DNA damage checkpoint responses in vivo (1, 2), we wanted to
ensure that the checkpoint responses to bulky adduct-contain-
ing plasmid DNA were independent of DNA ends. We there-
fore prepared AAF-modified, EcoRI-linearized plasmid DNA
and compared the Chk1 phosphorylation response to both cir-
cular and undamaged DNA. As shown in Fig. 3C, an identical,
4–5-fold stimulation of Chk1 phosphorylation was observed in
reactions containing either linearized or circular AAF-treated
DNA relative to undamaged DNA. To further verify these find-
ings and to determine whether other forms of damage, such as
DNA nicks, could induce Chk1 phosphorylation, we prepared
AAF-treated DNA with a pBluescript derivative modified to
FIGURE 3. Characterization of damaged DNA templates in the cell-free assay. A, kinase reactions containing either no DNA or unmodified (UM) or
BPDE-modified (M) circular plasmid DNA were performed as described. The graphed data for Chk1 phosphorylation was based on phosphorylation of Ser345,
although similar results were observed for phosphorylation of Ser317. Significantly more Chk1 phosphorylation was observed in reactions containing modified
DNA than in reactions lacking DNA or containing only unmodified DNA (paired t tests, p  0.01). A portion of the unmodified and BPDE-modified plasmid DNA
was electrophoresed on an agarose gel and stained with ethidium bromide to demonstrate the slower mobility caused by BPDE modification. B, kinase
reactions were prepared with either no DNA, unmodified DNA, AAF-modified DNA (AAF), or cisplatin-treated DNA (cisplatin; 1 or 10 M). Only the 100 M
cisplatin and AAF treatments induced significantly more Chk1 phosphorylation than reactions lacking DNA or containing unmodified DNA (paired t tests, p 
0.05). An ethidium bromide-stained agarose gel is shown to indicate the aberrant migration of the cisplatin- and AAF-modified DNA. C, circular or EcoRI-
linearized pUC19 DNA were left unmodified or were treated with AAF and then used in the in vitro kinase assay. Significant differences in Chk1 phosphorylation
were only observed in reactions containing modified DNA in comparison with reactions lacking DNA or containing unmodified DNA (paired t tests; p  0.05).
D, a pBluescript plasmid derivative containing two target sites for the nicking endonuclease Nt.BbvCI was left in circular form (Circ), nicked with Nt.BbvCI (Nick),
or linearized with EcoRI (Lin) before being treated or not with AAF. Significant differences in Chk1 phosphorylation were only observed in reactions containing
modified DNA in comparison with reactions lacking DNA or containing unmodified DNA (paired t tests; p  0.05). The plasmids were analyzed on an ethidium
bromide-stained agarose gel to monitor mobility and then used in kinase assays. The graphs show the average and S.D. values (error bars) from 2–3 independ-
ent experiments.
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allownickingwith the endonucleaseNt.BbvCI.As shown in Fig.
3D, with each form of DNA (circular, nicked, or linear), stimu-
lation of Chk1 phosphorylation was only observed in reactions
containing AAF-treated DNA.We conclude from these results
that bulky DNA adducts formed by AAF and BPDE can directly
induce checkpoint responses independent of DNA ends or
nicks.
Identification of Bulky DNA Adduct-stimulated Kinases in
Nuclear Extracts—The PIKKs ATR, ATM, and DNA-PKcs, are
the major kinases activated by DNA damage in mammalian
cells. To identify whether one or more PIKKs was responsible
for the stimulation of Chk1 phosphorylation by bulky adduct-
containing DNA in these reactions, we initially took a pharma-
cological approach to inhibit one ormore of the PIKKs.We first
used caffeine, which at high concentrations inhibits all three
PIKKs (44, 45). As shown in Fig. 4 (compare lanes 1–3 with
lanes 4–6), caffeine completely prevented damaged DNA-
stimulated Chk1 phosphorylation.
To determine which of the three PIKKs was responsible for
the effect of damaged DNA on Chk1 phosphorylation, we then
tested theDNA-PK-specific chemical inhibitorNU7026, which
competes with ATP for binding to DNA-PK (46). As shown in
Fig. 4 (lanes 7–9), this inhibitor nearly completely abolished
Chk1 phosphorylation by damaged DNA, indicating a major
role for DNA-PK in this phosphorylation event. We also used
the ATM inhibitor KU-55933, which, although very selective
for ATM (IC50  12.9 nM), also inhibits DNA-PK at higher
concentrations (IC50  2.5 M) (47). As shown in Fig. 4 (lanes
10–15), the highest does of KU-55933 (10 M) led to a 70%
reduction in Chk1 phosphorylation in comparison with reac-
tions with DMSO as a control. The dominant role for DNA-PK
in checkpoint substrate phosphorylation in these reactions was
also observed when either p53 or RPA was used as substrate in
the reaction (data not shown). We conclude from the results
with these pharmacological agents that DNA-PK plays a major
role in the stimulation of checkpoint substrate protein phos-
phorylation by bulky adduct-containing DNA in this system.
We next took a genetic approach to identify the bulky DNA
adduct-stimulated kinase(s), by using nuclear extract from cells
lacking either DNA-PKcs or ATM. In Fig. 5A, we show results
of immunoblotting the nuclear extracts from XP-A cells, the
glioblastoma cell lines M059K and M059J, and the CHO cell
lines AA8 and V3. The M059K and M059J cell lines were
derived from a single patient glioblastoma, but the M059J line
was found to be radiosensitive (48). It was later found that
theM059J cell line lacks DNA-PKcs (49) and, due toATM gene
truncation (50), has a significant reduction in ATM protein
expression (51, 52). Defects in DNA-PKcs and ATM protein
expression in these cell lines were corroborated in Fig. 5A. We
then used these nuclear extracts to test for BPDE-damaged
DNA-stimulated Chk1 phosphorylation. As shown in Fig. 5B,
althoughChk1 phosphorylationwas induced by damagedDNA
in reactions containing nuclear extract from M059K cells, the
response was completely absent when nuclear extract from the
M059J line was used.
To further examine whether DNA-PKcs and/or ATM are
important for the response to damagedDNA, we compared the
CHOcell linesAA8 (wild-type) andV3 (lackingDNA-PKcs). As
shown in Fig. 5C, although reactions containing AA8 nuclear
extract showed a stimulation of Chk1 phosphorylation in
response to bulky DNA adducts, the response was inhibited by
60% in reactions containingV3 nuclear extract. To determine
the kinase responsible for the remaining Chk1 phosphorylation
in the V3 nuclear extract, we added the ATM inhibitor
KU-55933 to reactions and found that the residual damaged
DNA response was completely eliminated (Fig. 5D). We con-
clude from these results that both DNA-PKcs and ATM are
involved in inducing Chk1 phosphorylation in response to
bulky DNA adducts.
We then used biochemical methods to remove specific
PIKKs from the XP-A nuclear extract to further confirm the
identity of the bulky DNA damage-stimulated protein kinases.
We first depletedATRby incubatingXP-Anuclear extract with
a small GST-tagged fragment of the protein TopBP1, which is
known to directly bind to ATR (53). As shown in Fig. 6A, this
method specifically removed ATR but neither ATM or DNA-
PKcs from the extract. We then used the mock- and ATR-de-
pleted nuclear extract in kinase assays to monitor the phosphor-
ylation status ofChk1. Identical resultswere obtainedwith both
extracts, indicating that ATR was not responsible for inducing
Chk1 phosphorylation in these reactions. We next specifically
depleted ATM from XP-A nuclear extract by incubating the
extract with either nonspecific anti-rabbit IgG or an anti-ATM
antibody. As shown in Fig. 6B, removal of ATM from the
extract was efficient and specific and led to an approximately
40% reduction in AAF-DNA-induced Chk1 phosphorylation.
These results suggest a role for ATM in the response to AAF-
damaged DNA. We then depleted DNA-PKcs from XP-A
nuclear extract with antibodies against DNA-PKcs. Depletion
of DNA-PKcs led to a complete loss of Chk1 phosphorylation
(Fig. 6C). Importantly, identical results were obtained with
BPDE-damaged DNA and with p53 or RPA as the substrate
(data not shown). These results show that DNA-PKcs plays a
major role in inducing Chk1 phosphorylation in response to
bulky DNA damage and that ATM has a smaller role that is
possibly dependent, in part, on DNA-PK activity.
FIGURE 4. Chemical inhibitors indicate a role for DNA-PK in the stimula-
tion of checkpoint substrate phosphorylation by bulky adduct-contain-
ing DNA. Kinase reactions were supplemented with the indicated chemical
inhibitors and performed as described previously. Reactions lacked DNA ()
or were supplemented with either unmodified (UM) or AAF-modified (M)
pUC19 DNA. For reactions containing modified DNA and supplemented with
caffeine, NU7026, or KU-55933 (10 M), Chk1 phosphorylation was signifi-
cantly different compared with reactions with the solvent control (paired
t test, p  0.05). Error bars, S.D.
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PurifiedDNA-PK andATMAreDirectly Stimulated by Bulky
Adduct-containing DNA—Taken together, the pharmacologi-
cal, genetic, and biochemical approaches utilized in this in vitro
checkpoint assay indicated that DNA-PK and ATM may be
directly stimulated by bulkyDNA adducts to phosphorylate the
checkpoint targets p53, Chk1, and RPA. To test this directly, we
used purified DNA-PK that was free of any contaminating
ATM or ATR (Fig. 7A). We then used this purified DNA-PK
in kinase reactions as described above, where the purified
DNA-PK was used in place of nuclear extract. Similar to
reactions with nuclear extract, Chk1 phosphorylation by
DNA-PK was stimulated 4–5-fold by AAF-damaged DNA in
comparison with reactions containing undamaged DNA
(Fig. 7B). Similar results were obtained when p53 was used as
a substrate for DNA-PK (data not shown), indicating that the
substrates are largely interchangeable in these reactions.
This response may be independent of the Ku subunits of
DNA-PK because the stimulation by AAF-modified DNA is
significantly less than the canonical response to linearized
DNA (supplemental Fig. 1).
To test whether the phosphorylation of checkpoint sub-
strates by DNA-PK involved the specific recognition of bulky
adduct-containing DNA by DNA-PK, we set up an in vitro
DNA pull-down assay in which purified DNA-PK was incu-
bated with either unmodified or AAF-treated plasmid DNA
that had been linearized, biotinylated on both ends, and immo-
bilized on streptavidin-coupled magnetic beads. As shown in
Fig. 7C,3-foldmore DNA-PKwas retained on the AAF-dam-
aged DNA than on the undamaged DNA. Together, these
results show that DNA-PK can directly recognize bulky DNA
adducts to induce phosphorylation of checkpoint substrate
proteins.
Because the pharmacological, genetic, and biochemical
approaches also indicated a smaller role for ATM in inducing
Chk1 phosphorylation, we purified a FLAGepitope-tagged ver-
sion ofATM free ofDNA-PKcs andATR (Fig. 8A) and tested its
ability to phosphorylate Chk1. As shown in Fig. 8B, Chk1 phos-
phorylation was stimulated 3-fold by AAF-damaged DNA
when compared with reactions lacking DNA or containing
undamaged plasmidDNA.Aswas observed forDNA-PK,ATM
showed a slight binding preference for DNA containing bulky
AAF adducts (Fig. 8C). We conclude that both ATM and
DNA-PK can be directly stimulated by bulky adduct-contain-
ing DNA.
FIGURE 5. The use of extracts deficient in one or more PIKKs supports a role for DNA-PK and ATM in the stimulation of checkpoint substrate phos-
phorylation by bulky adduct-containing DNA. A, nuclear extract (10 g) from the indicated cell lines was separated by SDS-PAGE, transferred to nitrocel-
lulose, and then probed for the indicated proteins. B, kinase reactions containing 300 ng of M059J or M059K nuclear extract. Reactions lacked DNA () or were
supplemented with either unmodified (UM) or AAF-modified (M) pUC19 DNA. The level of Chk1 phosphorylation in the M059K extract reactions containing
AAF-modified DNA was significantly different from reactions lacking DNA or containing unmodified DNA (paired t test, p  0.05). C, kinase reactions containing
5 g of nuclear extract from either AA8 or V3 cells. A significant difference in Chk1 phosphorylation was observed when comparing the response to modified
DNA between the AA8 and V3 extract-containing reactions (paired t test, p  0.05). D, kinase reactions with V3 nuclear extract were supplemented with either
DMSO or the ATM inhibitor KU-55933 (10 M). A statistically significant effect of modified DNA on Chk1 phosphorylation was only observed in reactions
containing DMSO (paired t test, p  0.05). Error bars, S.D.
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DISCUSSION
Here we described a mammalian cell-free system for study-
ing DNA damage checkpoint responses to bulky DNA adducts.
Importantly, this system allowed an examination of DNA dam-
age checkpoint activation in the absence of DNA repair, tran-
scription stalling, and replication stress. Similarly, these nuclear
extracts lack the histone variantH2AX (data not shown), which
through phosphorylation and interaction with additional DDR
proteins is involved in early DNA damage responses and in
amplifying DNA damage response signaling (54). Thus, the
checkpoint protein phosphorylation events we observed in our
in vitro reactions occurred independent of the H2AX-depen-
dent responses that take place in vivo. Ultimately, this cell-free
system should be useful to examine how other protein factors,
including H2AX and other DNA-binding proteins, impact the
bulky DNA damage response. Similarly, other types of DNA
damage and alternative DNA structures can also be tested with
this system.
Using this in vitro assay, we have discovered a new mecha-
nismbywhich bulkyDNAdamage checkpoint signalingmay be
initiated: the direct recognition of bulky DNA adducts by the
protein kinases DNA-PK andATM. In vivo, checkpoint protein
phosphorylation induced by bulky DNA adducts is generally
thought to only occur during the processing of bulky DNA
adducts by nucleotide excision repair (12–17), by the stalling of
RNA andDNApolymerases at bulky DNAbase adducts (1, 2, 8,
9), or by the repriming ofDNAreplication downstreamof bulky
lesions (10, 11). However, due to dynamic regulation by other
regulatory factors, including various protein phosphatases (55),
cell signaling pathways and protein phosphorylation events
may occur very rapidly and only transiently in vivo. Thus, the
ability to observe the direct effects of bulky DNA adducts in
cells is severely limited by the many regulatory systems and
numerous DNA metabolic processes that occur simultane-
ously. The use of defined, cell-free or reconstituted systems
therefore may allow for the identification of novel mechanisms
regulating the cellular response to DNA damage.
Our previous reports that ATR can be activated by bulky
DNA adducts in vitro in the absence of additional DNA meta-
bolic processes (21, 22, 56) similarly indicate that there are
alternative mechanisms for activating ATR in the absence of
ssDNA and RPA.Our current findings that bulkyDNA adducts
similarly stimulate DNA-PK and ATM simply indicates that
additional mechanisms for inducing checkpoint protein phos-
phorylation may exist in vivo. Moreover, the observation that
our in vitro cell-free system results in protein phosphorylation
in the absence of ATR indicates that DNA-PK and ATM may
play a role in the direct recognition of bulky DNA adducts that
are not recognized by DNA repair, transcription, or DNA rep-
lication in vivo. Consistent with this hypothesis, we found that
inhibition of ATM and DNA-PK activity in XP-A cells leads to
an approximate 30% reduction in AAF-induced Chk1 phos-
phorylation (supplemental Fig. 2).
Interestingly, DNA-PK and ATM are primarily thought to
function in the response to a different physical form of DNA
damage, the DNA double-strand break. However, as is the case
for ATR activation, many studies on DNA-PK and ATM acti-
vation have focused on the protein-protein interactions that aid
the recruitment of the kinases to sites of DNA damage. For
example, just as ATR can be stably recruited to single-stranded
DNA regions through interaction of ATRIP with RPA,
DNA-PK and ATM are recruited to double strand breaks
FIGURE 6. Depletion of DNA-PK and ATM from XP-A nuclear extract inhibits the stimulation of checkpoint substrate phosphorylation by bulky
adduct-containing DNA. A, ATR was depleted from XP-A nuclear extract with a fragment of the protein TopBP1, as described under “Experimental Proce-
dures.” Mock- and ATR-depleted nuclear extract were separated by SDS-PAGE, transferred to nitrocellulose, and then probed to detect the indicated proteins
(top). Mock- and ATR-depleted nuclear extracts were used in kinase assays using standard reaction conditions (bottom). B, ATM was immunodepleted from
XP-A nuclear extract using anti-ATM antibody. Mock depletion was performed with rabbit IgG. Mock- and ATM-depleted nuclear extracts were analyzed by
Western blotting and probed for the indicated proteins (top). Mock- and ATM-depleted nuclear extracts were then used in kinase assays (bottom). The level of
Chk1 phosphorylation in reactions with mock- and ATM-depleted extract upon the addition of modified DNA was significantly different (paired t test, p  0.05).
C, DNA-PKcs was immunodepleted from XP-A nuclear extract with antibodies against DNA-PKcs. Mock depletion was performed with mouse IgG. Nuclear
extracts from the mock and DNA-PKcs depletions were analyzed by Western blotting and probed with antibodies against the indicated proteins (top). Mock-
and DNA-PKcs-depleted extracts were then used in kinase assays (bottom). The levels of Chk1 phosphorylation in all three DNA-PKcs-depleted reactions were
significantly different from those in the mock-depleted reactions (paired t test, p  0.05). Error bars, S.D.
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through interactions with the Ku80/70 and MRN (Mre11-
Rad51-Nbs1) complexes, respectively (1, 2, 20). Although these
interactions are undoubtedly important for robust responses to
certain forms ofDNAdamage, it remains unclear how the phys-
icochemical properties of these kinases and their direct inter-
actions with damaged DNAmay affect their catalytic activities.
The fact that DNA-PKcs, ATM, and ATR can all be stimu-
lated by bulky DNA adducts to phosphorylate checkpoint sub-
strates indicates that a common biochemical mechanism may
be responsible for kinase activation by bulky DNA damage.
Indeed, all three kinases have previously been shown to directly
bind to double-stranded DNA independent of DNA ends or
accessory proteins (24, 57–59). Moreover, examination of their
primary and higher order structures indicates potentially
important features that may control their kinase activities.
DNA-PKcs, ATM, and ATR are all very large polypeptides
(300–470 kDa), of which only 5–10% of the total sequence
comprises the kinase domain. A significant fraction of each
protein is composed of 40–55 repeats of theHEAT (huntingtin,
elongation factor 4A, protein phosphatase 2A (PP2A) subunit,
mTor) motif (60), which is a simple pair of anti-parallel -hel-
ices linked by a short intraunit turn. Individual HEAT repeats
are linked by short interunit turns, which can then stack to form
higher order scaffolding structures. Recent cryoelectron mi-
croscopy and x-ray crystallography studies of DNA-PKcs have
indeed confirmed that a large open ring cradle structure is
formed in large part by these HEAT repeats (61, 62).
AlthoughHEATmotifs oftenmediate direct protein-protein
interactions, additional data suggest that they may also be uti-
lized for protein association with DNA. Along these lines, we
note that the Bacillus cereus DNA glycosylase AlkD, which is
composed entirely of HEAT repeats, was recently shown to
recognize and bind alkylated and mismatch-containing DNA
via its HEAT repeats (63). Furthermore, recent molecular
dynamic simulations of PR65, the HEAT repeat-containing
subunit of PP2A, have indicated that HEAT repeat scaffolds
may be flexible and responsive to force, such that changes in the
HEAT repeat structure of PR65may lead to alterations in PP2A
substrate binding or catalysis (64). Thus, through their HEAT
repeats and alterations in higher order structure upon binding
bulky adduct-containing DNA, we speculate that the kinase
activities of ATR, ATM, andDNA-PKmay all be similarly stim-
ulated to phosphorylate substrate proteins. Regardless of the
mechanism by which DNA-PK, ATM, and ATR are stimulated
by bulky adduct-containing DNA, our observations that all
three kinases can be stimulated by similar DNA substrates indi-
FIGURE 7. Purified DNA-PK is stimulated by bulky adduct-containing
DNA. A, purified DNA-PK was fractionated by SDS-PAGE and then stained
with silver (left) or analyzed by Western blotting (right) with antibodies
against the indicated proteins. B, kinase assays were performed with purified
DNA-PK and either no DNA (), unmodified plasmid DNA (UM), or AAF-mod-
ified plasmid DNA (M). C, unmodified or AAF-modified pUC19 was immobi-
lized on magnetic beads and then incubated in kinase reactions (20 l) con-
taining purified DNA-PK but lacking ATP. The relative amount of DNA-PKcs
retained on the beads was quantified and normalized to the unmodified DNA
sample. A portion of the bead-immobilized DNA was also electrophoresed on
an ethidium bromide-stained agarose gel to serve as a loading control. Error
bars, S.D.
FIGURE 8. Purified ATM is stimulated by bulky adduct-containing DNA.
A, purified, FLAG-tagged ATM was fractionated by SDS-PAGE and then
stained with silver (left) or analyzed by Western blotting (right) with antibod-
ies against the indicated proteins. B, kinase assays were performed with puri-
fied FLAG-ATM and either no DNA (), unmodified plasmid DNA (UM), or
AAF-modified plasmid DNA (M). Significantly more Chk1 phosphorylation
was observed in reactions containing modified DNA than in reactions lacking
DNA or containing unmodified DNA (paired t test, p  0.05). C, unmodified or
AAF-modified pUC19 was immobilized on magnetic beads and then incu-
bated in kinase reactions (20 l) containing purified ATM but lacking ATP. The
relative amount of ATM retained on the beads was quantified and normalized
to the unmodified DNA sample. A portion of the bead-immobilized DNA was
also electrophoresed on an ethidium bromide-stained agarose gel to serve as
a loading control. Error bars, S.D.
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cate that these kinasesmay have partially redundant or overlap-
ping roles in the cellular response to bulky DNA adducts.
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